Both authors contributed equally. Conflicts of Interest: U.P. is a consultant of Dynavax/Rheinbiotech for scientific aspects of HBV vaccine development. S.K., T.B., C.D. and M.S. declare no conflict of interest.
Design of therapeutic vaccines: hepatitis B as an example
Article first published online: 29 SEP 2011
© 2011 The Authors. Microbial Biotechnology © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd
Special Issue: Microbial Vaccines and Immunomodulators. Guest Editors: Carlos A. Guzman, Ennio De Gregorio, Jan ter Meulen, and Martin Friede
Volume 5, Issue 2, pages 270–282, March 2012
How to Cite
Kutscher, S., Bauer, T., Dembek, C., Sprinzl, M. and Protzer, U. (2012), Design of therapeutic vaccines: hepatitis B as an example. Microbial Biotechnology, 5: 270–282. doi: 10.1111/j.1751-7915.2011.00303.x
- Issue published online: 20 FEB 2012
- Article first published online: 29 SEP 2011
- Received 7 July, 2011; revised 22 August, 2011; accepted 22 August, 2011.
Therapeutic vaccines are currently developed for chronic viral infections, such as human papillomavirus (HPV), human immunodeficiency virus (HIV), herpesvirus and hepatitis B (HBV) and C (HCV) virus infections. As an alternative to antiviral treatment or to support only partially effective therapy a therapeutic vaccine shall activate the patient's immune system to fight and finally control or ideally even eliminate the virus. Whereas the success of prophylactic vaccination is based on rapid neutralization of the invading pathogen by antibodies, virus control and elimination of infected cells require T cells. Therefore, induction of a multi-specific and multifunctional T-cell response against key viral antigens is a paradigm of therapeutic vaccination – besides activation of a humoral immune response to limit virus spread. In this review, we describe options to develop a therapeutic vaccine for chronic viral infections using HBV as a promising example.